These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28280607)

  • 1. Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials.
    Petrelli F; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
    J Gastrointest Oncol; 2017 Feb; 8(1):39-48. PubMed ID: 28280607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers.
    Petrelli F; Tomasello G; Barni S
    Eur J Cancer; 2017 May; 76():8-16. PubMed ID: 28262586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.
    Berruti A; Amoroso V; Gallo F; Bertaglia V; Simoncini E; Pedersini R; Ferrari L; Bottini A; Bruzzi P; Sormani MP
    J Clin Oncol; 2014 Dec; 32(34):3883-91. PubMed ID: 25349292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer.
    Gogate A; Ranjan S; Kumar A; Bhandari H; Papademetriou E; Kim I; Potluri R
    Front Oncol; 2023; 13():1119102. PubMed ID: 37205193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
    Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
    Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial.
    Fokas E; Fietkau R; Hartmann A; Hohenberger W; Grützmann R; Ghadimi M; Liersch T; Ströbel P; Grabenbauer GG; Graeven U; Hofheinz RD; Köhne CH; Wittekind C; Sauer R; Kaufmann M; Hothorn T; Rödel C;
    Ann Oncol; 2018 Jul; 29(7):1521-1527. PubMed ID: 29718095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogate end points for overall survival in breast cancer trials: A review.
    Fiteni F; Bonnetain F
    Breast; 2016 Oct; 29():44-8. PubMed ID: 27400447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials.
    Petrelli F; Tomasello G; Ghidini M; Lonati V; Passalacqua R; Barni S
    HPB (Oxford); 2017 Nov; 19(11):944-950. PubMed ID: 28764887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
    Bonnetain F; Bosset JF; Gerard JP; Calais G; Conroy T; Mineur L; Bouché O; Maingon P; Chapet O; Radosevic-Jelic L; Methy N; Collette L
    Eur J Cancer; 2012 Aug; 48(12):1781-90. PubMed ID: 22507892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer.
    Petrelli F; Coinu A; Lonati V; Barni S
    Int J Colorectal Dis; 2015 Apr; 30(4):447-57. PubMed ID: 25433820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials.
    George TJ; Allegra CJ; Yothers G
    Curr Colorectal Cancer Rep; 2015; 11(5):275-280. PubMed ID: 26321890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer.
    Korn EL; Sachs MC; McShane LM
    Ann Oncol; 2016 Jan; 27(1):10-5. PubMed ID: 26489443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.
    Harshman LC; Xie W; Moreira RB; Bossé D; Ruiz Ares GJ; Sweeney CJ; Choueiri TK
    Cancer; 2018 Mar; 124(5):925-933. PubMed ID: 29266178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surrogate endpoints for overall survival in lung cancer trials: a review.
    Fiteni F; Westeel V; Bonnetain F
    Expert Rev Anticancer Ther; 2017 May; 17(5):447-454. PubMed ID: 28399678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
    Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
    Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic response to neoadjuvant treatment in locally advanced rectal cancer and impact on outcome.
    Jalilian M; Davis S; Mohebbi M; Sugamaran B; Porter IW; Bell S; Warrier SK; Wale R
    J Gastrointest Oncol; 2016 Aug; 7(4):603-8. PubMed ID: 27563451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited.
    Diefenhardt M; Schlenska-Lange A; Kuhnt T; Kirste S; Piso P; Bechstein WO; Hildebrandt G; Ghadimi M; Hofheinz RD; Rödel C; Fokas E;
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual- and trial-level surrogacy in colorectal cancer.
    Buyse M; Burzykowski T; Michiels S; Carroll K
    Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
    de Groot S; Pijl H; Charehbili A; van de Ven S; Smit VTHBM; Meershoek-Klein Kranenbarg E; Heijns JB; van Warmerdam LJC; Kessels LW; Dercksen MW; Pepels MJAE; van Laarhoven HWM; Vriens BEPJ; Putter H; Fiocco M; Liefers GJ; van der Hoeven JJM; Nortier JWR; Kroep JR;
    Breast Cancer Res; 2019 Aug; 21(1):97. PubMed ID: 31455425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies.
    Tomasello G; Petrelli F; Ghidini M; Pezzica E; Passalacqua R; Steccanella F; Turati L; Sgroi G; Barni S
    Eur J Surg Oncol; 2017 Sep; 43(9):1607-1616. PubMed ID: 28347525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.